Author Contributions Conceived and designed the experiments: SF TF YN MI. Performed the experiments: YM SF HK MO ST. Analyzed the data: YM SF HK MO ST References 1. Aranguren XL, Verfaillie CM, Luttun A (2009) Emerging hurdles in stem cell therapy for peripheral vascular disease. J Mol Med 87: 3–16. 2. Matoba S, Tatsumi T, Murohara T, Imaizumi T, Katsuda Y, et al. (2008) Long- term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. Am Heart J 156: 1010–1018. 3. Phelps EA, Garcia AJ (2009) Update on therapeutic vascularization strategies. Regen Med 4: 65–80. 4. van Weel V, van Tongeren RB, van Hinsbergh VW, van Bockel JH, Quax PH (2008) Vascular growth in ischemic limbs: a review of mechanisms and possible therapeutic stimulation. Ann Vasc Surg 22: 582–597. 5. Kajiguchi M, Kondo T, Izawa H, Kobayashi M, Yamamoto K, et al. (2007) Safety and efficacy of autologous progenitor cell transplantation for therapeutic angiogenesis in patients with critical limb ischemia. Circ J 71: 196–201. 6. Sieveking DP, Ng MK (2009) Cell therapies for therapeutic angiogenesis: back to the bench. Vasc Med 14: 153–166. 7. Cheng AS, Yau TM (2008) Paracrine effects of cell transplantation: strategies to augment the efficacy of cell therapies. Semin Thorac Cardiovasc Surg 20: 94–101. 8. Korf-Klingebiel M, Kempf T, Sauer T, Brinkmann E, Fischer P, et al. (2008) Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarction. Eur Heart J 29: 2851–2858. 9. Brenner W, Aicher A, Eckey T, Massoudi S, Zuhayra M, et al. (2004) 111In- labeled CD34+ hematopoietic progenitor cells in a rat myocardial infarction model. J Nucl Med 45: 512–518. 10. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD (2002) Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 105: 93–98. 11. Yau TM, Kim C, Li G, Zhang Y, Weisel RD, et al. (2005) Maximizing ventricular function with multimodal cell-based gene therapy. Circulation 112: I123–128. 12. Davis ME, Motion JP, Narmoneva DA, Takahashi T, Hakuno D, et al. (2005) Injectable self-assembling peptide nanofibers create intramyocardial microenvi- ronments for endothelial cells. Circulation 111: 442–450. 13. Narmoneva DA, Oni O, Sieminski AL, Zhang S, Gertler JP, et al. (2005) Self- assembling short oligopeptides and the promotion of angiogenesis. Biomaterials 26: 4837–4846. 14. Zhang G, Hu Q, Braunlin EA, Suggs LJ, Zhang J (2008) Enhancing efficacy of stem cell transplantation to the heart with a PEGylated fibrin biomatrix. Tissue Eng Part A 14: 1025–1036. 15. Aoki H (1994) Medical Applications of Hydroxyapatite. St. Louis: Ishiyaku EuroAmerica. 16. Furuzono T, Kishida A, Tanaka J (2004) Nano-scaled hydroxyapatite/polymer composite I. Coating of sintered hydroxyapatite particles on poly(gamma- methacryloxypropyl trimethoxysilane)grafted silk fibroin fibers through chemical bonding. J Mater Sci Mater Med 15: 19–23. 17. Furuzono T, Ueki M, Kitamura H, Oka K, Imai E (2009) Histological reaction of sintered nanohydroxyapatite-coated cuff and its fibroblast-like cell hybrid for an indwelling catheter. J Biomed Mater Res B Appl Biomater 89: 77–85. 18. Yanagida H, Okada M, Masuda M, Ueki M, Narama I, et al. (2009) Cell adhesion and tissue response to hydroxyapatite nanocrystal-coated poly(L-lactic acid) fabric. J Biosci Bioeng 108: 235–243. 19. Furuzono T, Masuda M, Okada M, Yasuda S, Kadono H, et al. (2006) Increase in cell adhesiveness on a poly(ethylene terephthalate) fabric by sintered hydroxyapatite nanocrystal coating in the development of an artificial blood vessel. ASAIO J 52: 315–320. 20. Fujii S, Okada M, Sawa H, Furuzono T, Nakamura Y (2009) Hydroxyapatite nanoparticles as particulate emulsifier: fabrication of hydroxyapatite-coated biodegradable microspheres. Langmuir 25: 9759–9766. 21. Rezwan K, Chen QZ, Blaker JJ, Boccaccini AR (2006) Biodegradable and bioactive porous polymer/inorganic composite scaffolds for bone tissue engineering. Biomaterials 27: 3413–3431. 22. Nakagawa M, Teraoka F, Fujimoto S, Hamada Y, Kibayashi H, et al. (2006) Improvement of cell adhesion on poly(L-lactide) by atmospheric plasma treatment. J Biomed Mater Res A 77: 112–118. 23. Okada M, Furuzono T (2007) Calcination of Rod-like Hydroxyapatite Nanocrystals with an Anti-sintering Agent Surrounding the Crystals. Journal of Nanoparticle Research 9: 807–815. 24. Okada M, Furuzono T (2010) Hydroxyapatite nanocrystal coating on biodegradable microspheres. Materials Science and Engineering: B 173: 199–203. 25. Takahashi M, Li TS, Suzuki R, Kobayashi T, Ito H, et al. (2006) Cytokines produced by bone marrow cells can contribute to functional improvement of the infarcted heart by protecting cardiomyocytes from ischemic injury. Am J Physiol Heart Circ Physiol 291: H886–893. Nano-Scaffold for Therapeutic Angiogenesis TS ME TF YN MI. Contributed reagents/materials/analysis tools: YM SF MO TF. Wrote the paper: YM SF HK MO TF MI. 26. Couffinhal T, Silver M, Zheng LP, Kearney M, Witzenbichler B, et al. (1998) Mouse model of angiogenesis. Am J Pathol 152: 1667–1679. 27. Iba O, Matsubara H, Nozawa Y, Fujiyama S, Amano K, et al. (2002) Angiogenesis by implantation of peripheral blood mononuclear cells and platelets into ischemic limbs. Circulation 106: 2019–2025. 28. Abbott JD, Huang Y, Liu D, Hickey R, Krause DS, et al. (2004) Stromal cell- derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation 110: 3300–3305. 29. Clausen BH, Lambertsen KL, Babcock AA, Holm TH, Dagnaes-Hansen F, et al. (2008) Interleukin-1beta and tumor necrosis factor-alpha are expressed by different subsets of microglia and macrophages after ischemic stroke in mice. J Neuroinflammation 5: 46. 30. Shoji T, Koyama H, Morioka T, Tanaka S, Kizu A, et al. (2006) Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes. Diabetes 55: 2245–2255. 31. Zhuang ZW, Gao L, Murakami M, Pearlman JD, Sackett TJ, et al. (2006) Arteriogenesis: noninvasive quantification with multi-detector row CT angiog- raphy and three-dimensional volume rendering in rodents. Radiology 240: 698–707. 32. Ignatius AA, Claes LE (1996) In vitro biocompatibility of bioresorbable polymers: poly(L, DL-lactide) and poly(L-lactide-co-glycolide). Biomaterials 17: 831–839. 33. Schakenraad JM, Hardonk MJ, Feijen J, Molenaar I, Nieuwenhuis P (1990) Enzymatic activity toward poly(L-lactic acid) implants. J Biomed Mater Res 24: 529–545. 34. Williams DF, Mort E (1977) Enzyme-accelerated hydrolysis of polyglycolic acid. J Bioeng 1: 231–238. 35. Anderson JM, Rodriguez A, Chang DT (2008) Foreign body reaction to biomaterials. Semin Immunol 20: 86–100. 36. Lehto M, Duance VC, Restall D (1985) Collagen and fibronectin in a healing skeletal muscle injury. An immunohistological study of the effects of physical activity on the repair of injured gastrocnemius muscle in the rat. J Bone Joint Surg Br 67: 820–828. 37. Kondo K, Shintani S, Shibata R, Murakami H, Murakami R, et al. (2009) Implantation of adipose-derived regenerative cells enhances ischemia-induced angiogenesis. Arterioscler Thromb Vasc Biol 29: 61–66. 38. Dubois G, Segers VF, Bellamy V, Sabbah L, Peyrard S, et al. (2008) Self- assembling peptide nanofibers and skeletal myoblast transplantation in infarcted myocardium. J Biomed Mater Res B Appl Biomater 87: 222–228. 39. Suuronen EJ, Veinot JP, Wong S, Kapila V, Price J, et al. (2006) Tissue- engineered injectable collagen-based matrices for improved cell delivery and vascularization of ischemic tissue using CD133+ progenitors expanded from the peripheral blood. Circulation 114: I138–144. 40. Qin SL, Li TS, Kubo M, Ohshima M, Furutani A, et al. (2008) Transient increase of cytokines in the acute ischemic tissue is beneficial to cell-based therapeutic angiogenesis. Circ J 72: 2075–2080. 41. Cho HJ, Lee N, Lee JY, Choi YJ, Ii M, et al. (2007) Role of host tissues for sustained humoral effects after endothelial progenitor cell transplantation into the ischemic heart. J Exp Med 204: 3257–3269. 42. Takahashi M (2010) Role of the SDF-1/CXCR4 system in myocardial infarction. Circ J 74: 418–423. 43. Kamihata H, Matsubara H, Nishiue T, Fujiyama S, Tsutsumi Y, et al. (2001) Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation 104: 1046–1052. 44. Tateno K, Minamino T, Toko H, Akazawa H, Shimizu N, et al. (2006) Critical roles of muscle-secreted angiogenic factors in therapeutic neovascularization. Circ Res 98: 1194–1202. 45. Wragg A, Mellad JA, Beltran LE, Konoplyannikov M, San H, et al. (2008) VEGFR1/CXCR4-positive progenitor cells modulate local inflammation and augment tissue perfusion by a SDF-1-dependent mechanism. J Mol Med (Berl) 86: 1221–1232. 46. Awad O, Dedkov EI, Jiao C, Bloomer S, Tomanek RJ, et al. (2006) Differential healing activities of CD34+ and CD14+ endothelial cell progenitors. Arterioscler Thromb Vasc Biol 26: 758–764. 47. Hiasa K, Ishibashi M, Ohtani K, Inoue S, Zhao Q, et al. (2004) Gene transfer of stromal cell-derived factor-1alpha enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: next-generation chemokine therapy for therapeutic neovascularization. Circulation 109: 2454–2461. 48. Malafaya PB, Silva GA, Reis RL (2007) Natural-origin polymers as carriers and scaffolds for biomolecules and cell delivery in tissue engineering applications. Adv Drug Deliv Rev 59: 207–233. PLoS ONE | www.plosone.org 11 April 2012 | Volume 7 | Issue 4 | e35199